Is It Finally Time for Pharma to Change the Way It Uses Facebook?

Is It Finally Time for Pharma to Change the Way It Uses Facebook?

Pharma has hidden behind the ability to turn commenting off on Facebook pages, allowing marketers to use the channel much as they would a typical web page.

Five things for pharma marketers to know: Friday, August 28

Five things for pharma marketers to know: Friday, August 28

Amgen's Repatha receives FDA nod; Mylan shareholders vote in favor of Perrigo deal; doctors push for below-average price of experimental cancer drug

Washington Insider: A New Report

Washington Insider: A New Report

Back Talk: Hail to the . . . CEO?

Back Talk: Hail to the . . . CEO?

Private View: Bonnie Overton

Private View: Bonnie Overton

Partner Forum: Will predictive analytics sell?

Can predictive analytics, embedded into CRM, fulfill the promise on which closed-loop marketing fell short: Allow pharma to harness data from rep visits to make their upcoming digital sales pitches smarter?

The FDA approves second PCSK9 inhibitor, Repatha

The FDA approves second PCSK9 inhibitor, Repatha

Amgen's Repatha will come to market priced $500 lower than the cost of Sanofi and Regeneron's Praluent.

Sunovion prepares for FDA decision on Aptiom

Sunovion prepares for FDA decision on Aptiom

The FDA is expected to announce this week whether it has approved the epilepsy drug as a monotherapy for partial-onset seizures.

Five things for pharma marketers to know: Thursday, August 27

Five things for pharma marketers to know: Thursday, August 27

The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision

Social Engagement: Leveling the Field

Social Engagement: Leveling the Field

Social media has the potential to elevate challenger brands to the highest step on the podium. But with many companies still languishing in the blocks, medal-worthy performances remain few and far between. It's time for pharma to step up its social game, as James Chase reports

What Wearables Can Deliver for Marketers

What Wearables Can Deliver for Marketers

Excitement about wearables like the Apple Watch or Fitbit sometimes fuels unrealistic hype about healthcare marketing opportunities.

CHC and CCC partner to offer regulatory education to agencies

CHC and CCC partner to offer regulatory education to agencies

The compliance "university" aims to help healthcare agencies and publishers stay up to date on the latest regulatory changes.

Five things for pharma marketers to know: Wednesday, August 26

Five things for pharma marketers to know: Wednesday, August 26

Medicaid officials urged to expand access to hepatitis-C drugs; Perrigo is looking to make acquisitions; Sarepta's experimental therapy gets priority review

Brand Development Strategies: Golden Oldies

Brand Development Strategies: Golden Oldies

The rise of digital promotion and the need to wring every last drop of ROI from successful products have created a new niche: one with shoestring budgets, little to no sales-force support and competitors ready to pounce. Frank Celia explores late-lifecycle marketing and the companies and brands that manage to flourish there

Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead

Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead

Longtime ICC leader Viviano moves to the client side to help the start-up build its marketing team and become a commercial contender.

Inovalon scoops up consultancy Avalere Health

Inovalon scoops up consultancy Avalere Health

The cloud technology firm announced it will acquire Avalere in a move aimed at growing its relationships with pharma.

Five things for pharma marketers to know: Tuesday, August 25

Five things for pharma marketers to know: Tuesday, August 25

US patent office declines to review two Ampyra patents; the FDA expands indication for Promacta; the Biosimilars Council argues against CMS proposal for biosimilar coding

Patient Education/Marketing Report: Revolution

Patient Education/Marketing Report: Revolution

Patient education used to be a cookie-cutter operation: Hire a spokesperson, plan an event and draft a static list of symptoms, then call it a day. But in the wake of groundbreaking campaigns from AstraZeneca and Novartis, the industry may well have to raise its content-creation game—and cede considerable control to super-informed patients in the process. Larry Dobrow reports on the two programs that have raised the ­ patient-ed stakes

Will Pharma Have an Ashley Madison Moment?

Will Pharma Have an Ashley Madison Moment?

Ashley Madison's lesson must be heeded. For all the good pharma has done for the world, it has also created its share of ethical quagmires.

Publicis hangs out healthcare shingle in Singapore

Publicis hangs out healthcare shingle in Singapore

Publicis Healthcare Singapore will launch in September.

Eliquis DTC: "Cardiac Resuscitation"

Eliquis DTC: "Cardiac Resuscitation"

Larry Dobrow talks to guest, Michael Maher, President, ID Health, about the advertising for BMS/Pfizer's oral blood thinner Eliquis, whose DTC campaign launched last year.

Five things for pharma marketers to know: Monday, August 24

Five things for pharma marketers to know: Monday, August 24

AstraZeneca inks cancer development deal; beta-blockers may increase survival in ovarian-cancer patients; OPDP finds corrective ads are ineffective

Experts: Sprout needs to show Addyi is not Viagra for women

Experts: Sprout needs to show Addyi is not Viagra for women

Contrary to popular belief, Addyi is not the female Viagra. That's the message drug-maker Sprout must get across to doctors and patients in the coming weeks.

Headliner: Sales vet keeps 111-year-old title spry

Headliner: Sales vet keeps 111-year-old title spry

Amy Clarke Luchsinger "thinks that HCPs want both digital and print. The people [she] talks with just want to be able to access information when and where they want it . . .

Five things for pharma marketers to know: Friday, August 21

Five things for pharma marketers to know: Friday, August 21

The FDA encourages clinical testing of testosterone; Google spins out its life-sciences business; Novartis buys remaining rights to Arzerra

The MM&M Weekly News Quiz: August 21

The MM&M Weekly News Quiz: August 21

Test your knowledge in this week's edition of the MM&M Weekly News Quiz.

Professional Ad Report: Staying Power

Professional Ad Report: Staying Power

Print has been written off so often as being obsolete and unwieldy that it seems a wonder that it is still with us. So why does Kantar Media data for the first half of 2015 suggest that print remains vital? Rebecca Mayer Knutsen breaks down the numbers—and through the conventional wisdom

Poll: Majority of Americans support government negotiation of drug prices

Poll: Majority of Americans support government negotiation of drug prices

A new poll conducted by the Kaiser Family Foundation found that most Americans believe drugmakers should be required to release information to the public about how they set drug prices.

New data sets up Jardiance to displace DPP-4 inhibitors

New data sets up Jardiance to displace DPP-4 inhibitors

Eli Lilly's and BI's diabetes medication Jardiance becomes the first blood glucose-lowering drug to demonstrate it can reduce the risk of heart attack and stroke.

Five things for pharma marketers to know: Thursday, August 20

Five things for pharma marketers to know: Thursday, August 20

Valeant acquires Sprout for $1 billion; AbbVie buys Priority Review voucher from United Therapeutics; FDA approval rate stands at 89% so far for 2015.

Editor's Desk: Kim Kardashian West's tempest in a bottle

Editor's Desk: Kim Kardashian West's tempest in a bottle

Could Kardashian West's now-notorious Diclegis social post be more than an OPDP case study?

The FDA approves sex-drive pill, Addyi

The FDA approves sex-drive pill, Addyi

Sprout plans to hire 200 sales reps, targeting 30,000 doctors, to accompany the drug's launch.

Five things for pharma marketers to know: Wednesday, August 19

Five things for pharma marketers to know: Wednesday, August 19

Sprout's controversial sexual-desire drug receives FDA approval; prescription-drug coverage impacts cash sales at Walmart; Mylan warned about manufacturing violations

Therapeutic Focus: Women's Health

Therapeutic Focus: Women's Health

From hormone-replacement therapies to super-effective breast-cancer drugs to the so-called female Viagra, innovation within the women's health category has accelerated in recent months.

Amgen settles off-label case with states

Amgen settles off-label case with states

State attorneys general accused the drugmaker of violating state consumer protection laws.

Can Marketing Accelerate the Health Insurance Buying Cycle?

Can Marketing Accelerate the Health Insurance Buying Cycle?

Some folks move through their healthcare buying cycle relatively quickly and others may take a year, but everyone generally goes through the phases of discovering a need, shopping around, narrowing the field and making a decision.

Five things for pharma marketers to know: Tuesday, August 18

Five things for pharma marketers to know: Tuesday, August 18

Biogen to map ALS genes with Ice Bucket Challenge funds; Merck seeks first-line indication for Keytruda; lawmaker criticizes FDA approval of OxyContin for children

Purdue debuts opioid-abuse resource

Purdue debuts opioid-abuse resource

Purdue Pharma launched a new resource around the abuse-deterrent properties of some of its painkillers.

What to expect in wake of the Amarin ruling: more truthful off-label talk from pharma

What to expect in wake of the Amarin ruling: more truthful off-label talk from pharma

But don't expect the floodgates to open. Marketers still have to take a legal route to promote such information.

Five things for pharma marketers to know: Monday, August 17

Five things for pharma marketers to know: Monday, August 17

Court blocks generic competition for Opana ER until 2023; lawmakers question Valeant drug price hikes; Roche's immuno-oncology drug meets primary endpoint in mid-stage trial

The MM&M Weekly News Quiz: August 14

The MM&M Weekly News Quiz: August 14

Test your knowledge in this week's edition of the MM&M Weekly News Quiz

Five things for pharma marketers to know: Friday, August 14

Five things for pharma marketers to know: Friday, August 14

GSK studying Breo Ellipta in lung-cancer patients; researchers develop strains of yeast for painkillers in a lab; Wolters Kluwer acquires CME provider

ViiV Healthcare hires Porter Novelli for corporate comms

ViiV Healthcare hires Porter Novelli for corporate comms

ViiV Healthcare, a joint venture by Pfizer and GlaxoSmithKline, has appointed Porter Novelli to manage its corporate comms account, PRWeek understands.

Most docs are in the dark about biosimilars: survey

Most docs are in the dark about biosimilars: survey

Less than half of 300 doctors polled in a QuantiaMD survey could name a biosimilar that's under consideration for approval, and only 17% said they're very likely to prescribe one.

We're searching for 2015's Outstanding Contributor to Healthcare

We're searching for 2015's Outstanding Contributor to Healthcare

Know a very special person or group making extraordinary contributions to public health? We want to hear from you.

Five things for pharma marketers to know: Thursday, August 13

Five things for pharma marketers to know: Thursday, August 13

The FDA pushed back Opdivo's PDUFA date in light of new data; lawmakers argue about vet co-pays; Merck and MD Anderson Cancer Center to evaluate Keytruda in stomach and liver cancers

Is It Time to Change the Vaccine Dialogue? Campaigns Present Opportunities for Pharma

Is It Time to Change the Vaccine Dialogue? Campaigns Present Opportunities for Pharma

While social media can be a tool for pharma to help educate the public, it has also become a forum for the public to express their views about pharma, and it's not always flattering, as evidenced by the recent antivaccine movement.

Everyday Health expects growth from consolidated offerings and specialty brands

Everyday Health expects growth from consolidated offerings and specialty brands

The media company said orphan drugs and specialty medicines, like PCSK9 inhibitors, will drive the company's business going forward.

Five things for pharma marketers to know: Wednesday, August 12

Five things for pharma marketers to know: Wednesday, August 12

J&J turns to digital marketing in China; GSK closes North Carolina facility; Kim Kardashian West's promotion of Diclegis increased online conversations about the brand

Everyday Health buys hospital marketing firm

Everyday Health buys hospital marketing firm

The company acquired Tea Leaves Health for $30 million to diversify its business.

Bad ad watchdog slams Kardashian's social-media post

Bad ad watchdog slams Kardashian's social-media post

The FDA said Kim Kardashian West's promotion of morning-sickness pill Diclegis misbranded the product by understating its risks.

Five things for pharma marketers to know: Tuesday, August 11

Five things for pharma marketers to know: Tuesday, August 11

"Me-too" drugs may help lower costs; start-ups send doctors to your home; the FDA is likely to appeal the Amarin ruling

How Direct Marketing Must Adapt in Today's Healthcare System

How Direct Marketing Must Adapt in Today's Healthcare System

By breaking down traditional organizational silos to bring together the chief medical officer and the chief marketing officer, companies can unite the forces of clinical best practices with direct-to-consumer response marketing.

PCSK9 inhibitors necessitate an update to heart guidelines, CVS Health says

The pharmacy benefit manager said that the introduction of new treatments and clinical evidence on statins demands a rethink to ACC/AHA guidelines

Five things for pharma marketers to know: Monday, August 10

Five things for pharma marketers to know: Monday, August 10

CVS will not negotiate PCSK9 inhibitor pricing until Amgen's Repatha receives approval; more companies are looking inward for marketing help in lieu of agencies; AstraZeneca inks oncology collaboration

Judge grants relief to Amarin in off-label case

Judge grants relief to Amarin in off-label case

The decision, a setback for the FDA, allows the drugmaker to move forward with plans to legally promote some off-label information.

The MM&M Weekly News Quiz: August 7

The MM&M Weekly News Quiz: August 7

Test your knowledge in this week's edition of the MM&M Weekly News Quiz.

Five things for pharma marketers to know: Friday, August 7

Five things for pharma marketers to know: Friday, August 7

CVS excludes 31 drugs including Viagra from its 2016 formulary; Sanofi partners with Evotec on stem-cell treatment development; primary-care physicians may hesitate to prescribe Truvada for PrEP

Allergan sales rise on "strong" DTC advertising

Allergan sales rise on "strong" DTC advertising

Allergan executives attributed strong sales of branded products to recent investments in direct-to-consumer advertising.

Novo Nordisk says any tussle with Sanofi's Toujeo will come down to formulary access

Novo Nordisk says any tussle with Sanofi's Toujeo will come down to formulary access

The Danish drugmaker said it expects an FDA decision about long-acting—and long-delayed—insulin Tresiba in October.

Five things for pharma marketers to know: Thursday, August 6

Five things for pharma marketers to know: Thursday, August 6

AstraZeneca signs two immuno-oncology collaboration deals; UK cost watchdog goes after Pfizer over epilepsy medication price tag; Boston Globe reports drugmakers are funneling more money through CME programs

Drugs that turn cancer into a chronic disease need new marketing strategies: report

Drugs that turn cancer into a chronic disease need new marketing strategies: report

Findings of a new report suggest ways pharma should rethink its commercial and R&D decisions in light of improved survival rates associated with some cancers.

Astellas to use rugby to promote prostate-cancer awareness

The drugmaker, which sells prostate-cancer treatment Xtandi, wants social-media users to help spread the word about the disease

Five things for pharma marketers to know: Wednesday, August 5

Five things for pharma marketers to know: Wednesday, August 5

The FDA updates Gilenya's label over definite case of PML; generic drug companies are consolidating for negotiating power; the FDA revises guidance on DTC risk information

Firms promising Rx savings deepen ties to EHR platforms

Recent deals show these companies are expanding their EHR networks, and the number of physicians who gain access to copay coupons, vouchers and other forms of assistance.

Eylea erodes Lucentis, Avastin market share

Eylea erodes Lucentis, Avastin market share

Eylea's robust second quarter of sales can be attributed in part to its ability to erase market share of competitors.

FDA okays 3-D print technology for drug

Spritam is a prescription epilepsy adjunct delivered orally.

Five things for pharma marketers to know: Tuesday, August 4

Five things for pharma marketers to know: Tuesday, August 4

Shire offers to buy Baxalta for $30 billion; CVS reports strong sales in specialty pharmacy; Reuters reports that new drug launches hit 17-year high in 2014

Express Scripts drops Onglyza from 2016 formulary over safety concerns

Express Scripts drops Onglyza from 2016 formulary over safety concerns

The PBM said AstraZeneca's diabetes medications Onglyza and Kombiglyze XR will not be covered next year.

Healthcare reimagined: Fortner finesses McKesson's bold vision

Healthcare reimagined: Fortner finesses McKesson's bold vision

From evolving healthcare laws to social engagement, litigation crises to media relations, McKesson's PR chief is hands-on in efforts to enhance the brand's image.

Five things for pharma marketers to know: Monday, August 3

Five things for pharma marketers to know: Monday, August 3

Shire buys Foresight Biotherapeutics for $300 million; Novartis sold off three investigational drugs into Mereo BioPharma; new blood thinners linked to 8,000 deaths since 2010

Cannes Roundtable: What's Really next for Pharma?

McCann Health hosted a lively debate on the future of pharma branding at the Cannes Lions Health international creative festival. MM&M sister publication Campaign listened in

Back Talk: Is Cost Myopia Unfocused?

Back Talk: Is Cost Myopia Unfocused?

Before you fire up your outrage and vent your spleen, take a long look inside your parents' (or your own) medicine chest

Private View: The Lions Share

Private View: The Lions Share

What to do next year to be sure to see your agency's efforts highlighted in the big-time venue Lions Health

MM&M Awards 2015: The Short List

MM&M Awards 2015: The Short List

More than 100 handpicked healthcare marketing professionals spent hours analyzing and debating your MM&M Awards entries. Here are the ones that made the finalist cut

Viewpoint: The Ultimate Competitive Advantage

Viewpoint: The Ultimate Competitive Advantage

Partner Forum: Are Wearables a Pharma Field Day?

The arrival of the Apple Watch—following hardware from Samsung and others—has sparked interest among app developers for use in consumer healthcare. Do wearables have a role in life-science sales and CRM?

Washington Insider: 21st Century Cures

Washington Insider: 21st Century Cures

Passing the 21st Century Cures Act was a bipartisan success due to open lines of dialogue among stakeholders

The MM&M Weekly News Quiz: July 31

The MM&M Weekly News Quiz: July 31

Test your knowledge in this week's edition of the MM&M Weekly News Quiz.

Five things for pharma marketers to know: Friday, July 31

Five things for pharma marketers to know: Friday, July 31

Lawsuit alleges CVS overbilled insurance companies for generic drugs; a Merck vaccine is shown to be effective in treating Ebola; the FDA approves Bayer's rosacea treatment

Wunderman Health acquires ABS Creative

The New York-based agency took a majority stake in the full-service healthcare agency.

Sanofi launches DTC campaign for Afrezza

Sanofi launches DTC campaign for Afrezza

The "Surprise, it's insulin" campaign follows criticism of the lower-than-expected sales of the inhaled insulin since its launch in February.

Five things for pharma marketers to know: Thursday, July 30

Five things for pharma marketers to know: Thursday, July 30

Copaxone sales rise despite generic competition; Valeant to defend tax strategy; Bristol-Myers Squibb to test Opdivo with mogamulizumab in the US

Cloud Marketing: Cloud Control

Cloud Marketing: Cloud Control

To unlock the vast business potential of the cloud, pharma must first overcome its inherent resistance to change and then commit to tearing down those silo walls. James Chase reports

Eyeing big returns, drugmakers ready new hepatitis-C drug launches

Eyeing big returns, drugmakers ready new hepatitis-C drug launches

More patients are seeking treatments with even fewer side effects and shorter durations.

Turing names J&J vet for chief comms role

Turing Pharmaceuticals hired Craig Rothenberg, who spent 20 years with Johnson & Johnson, to lead the recently founded drugmaker's communications operations.

Five things for pharma marketers to know: Wednesday, July 29

Five things for pharma marketers to know: Wednesday, July 29

Drug spending projected to grow at 6% clip through 2024, spurred in part by pricey new medications; FDA approves new obesity device; Sanofi diabetes combo drug is better at reducing blood glucose than Lantus.

Graphic: the new hepatitis-C drug market

Graphic: the new hepatitis-C drug market

View on a quarter-by-quarter basis the competitive market for four new hepatitis-C treatments and track how Gilead Sciences' Harvoni became the market leader within months of receiving approval from the FDA.

Point of Care: Point of Where?

Point of Care: Point of Where?

With rare exceptions, the point of care used to be one of three places: the doctor's office, the hospital or the pharmacy. But with advancing technology and connectivity facilitating physician-patient sessions that can take place with one—or both—participants lounging on the beach, the point of care is now officially wherever patients want it to be. Rebecca Mayer Knutsen reports

Merck's Keytruda gains market share in Q2

Merck's Keytruda gains market share in Q2

The immuno-oncology drug is competing with Bristol-Myers Squibb's Opdivo.

Pfizer ends bid for OTC Lipitor

Pfizer ends bid for OTC Lipitor

The drugmaker told investors that the actual-use trial failed to meet the primary objectives.

Five things for pharma marketers to know: Tuesday, July 28

Five things for pharma marketers to know: Tuesday, July 28

Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe

Biotech Report: Will Gene Therapy Go Mainstream?

Biotech Report: Will Gene Therapy Go Mainstream?

The products are safe. The science is rock-solid. Patients are champing at the bit. But as much as the industry may be lining up behind gene therapies, marketing and operational questions abound. Larry Dobrow reports on the current state of the gene therapy union


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.